Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | ACLY | P53396 | 3/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5130040 | 0.91 | MEN1 (0.39) | TDP1TSHRLMNAMEN1KMT2A | |
| SCHEMBL4475594 | 0.89 | KDM4E (0.40) | TDP1TSHRMEN1KMT2AACLY | |
| SCHEMBL4484350 | 0.87 | TDP1 (0.36) | TDP1TSHRLMNAKDM4E | |
| SCHEMBL493617 | 0.86 | KMT2A (0.42) | P2RY2LMNAKMT2ATBXA2R | |
| SCHEMBL493087 | 0.83 | TDP1 (0.43) | TDP1TSHRP2RY2LMNAL3MBTL1 | |
| SCHEMBL493229 | 0.80 | ALDH1A1 (0.42) | P2RY2KMT2ATBXA2RPTGDR2KDM4E | |
| SCHEMBL4461535 | 0.78 | FABP4 (0.43) | LMNAL3MBTL1FABP4MEN1KMT2A | |
| SCHEMBL5114277 | 0.77 | ALDH1A1 (0.40) | KMT2APTGDR2KDM4E | |
| SCHEMBL5125393 | 0.75 | KMT2A (0.39) | TDP1TSHRP2RY2KMT2A | |
| SCHEMBL571406 | 0.75 | BDKRB1 (0.37) | TDP1TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| EP-2139851-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | TDP1 3893/4885TSHR 4051/4885P2RY2 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.